Severe asthma in the US population and eligibility for mAb therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Severe asthma in the US population and eligibility for mAb therapy

Published:2020-04 Issue:4 Volume:145 Page:1295-1297.e6
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Akenroye Ayobami,McCormack Meredith,Keet Corinne

Funder

National Institute of Allergy and Infectious Diseases

Pediatric Allergy and Immunology

Johns Hopkins University

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference14 articles.

1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014

2. The prevalence of severe refractory asthma;Hekking;J Allergy Clin Immunol,2015

3. Monoclonal antibodies for the treatment of refractory asthma;Hambly;Curr Opin Pulm Med,2014

4. Nonadherence in the era of severe asthma biologics and thermoplasty;Lee;Eur Respir J,2018

5. Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma;Comberiati;J Allergy Clin Immunol Pract,2019

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics;Respiratory Medicine;2024-11

2. RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists;Journal of Personalized Medicine;2024-08-12

3. Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions;Journal of Allergy and Clinical Immunology;2024-08

4. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations;The Journal of Allergy and Clinical Immunology: In Practice;2024-06

5. Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level;Scientific Reports;2024-05-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3